Guide contents
Open in calculatorCompound briefing
BPC-157 (Body Protection Compound) is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in gastric juice. Across preclinical research it has been studied extensively for cytoprotection, accelerated soft-tissue recovery, tendon-to-bone healing, and gut lining repair — with pleiotropic activity across multiple organ systems.
The research question
BPC-157 research centres on cytoprotection rather than one isolated disease target. The central question is whether its effects on nitric oxide, growth-factor signalling and cell migration can produce reproducible tissue repair beyond animal models.
Mechanism & research themes
Acts via upregulation of the nitric oxide (NO) system, modulation of VEGF/EGF growth factor signalling, and activation of the FAK-paxillin pathway to accelerate fibroblast migration and tissue remodelling. Demonstrates both peripheral and central activity.
Studied for accelerated tendon, ligament and muscle repair
Researched for gastric ulcer and IBD-model gut healing
Neuroprotection and recovery in TBI animal models
Suppression of NF-κB and pro-inflammatory cytokines
Enhanced callus formation in fracture-repair research
Cytoprotective effects across multiple organ systems
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
The literature is dominated by rodent and cell studies. Human pharmacokinetic and controlled efficacy data remain insufficient for firm clinical conclusions.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 200–500mcg per day subcutaneously (approximately 2–10mcg/kg), administered once or twice daily, in 4–12 week cycles. 8 weeks on / 4 weeks off is a frequently cited schedule.
Reported persistence
approximately 4 hours (animal pharmacokinetic estimates; human PK data remains limited)
Calculator starting point
0.3 mg per reference dose
7 doses per week · 8-week cycle
2 mL default reconstitution volume
Typical research range 200–500 mcg/day SC for 4–12 weeks.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate BPC-157Laboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 2mL of bacteriostatic water, injected slowly down the side of the vial, for a 2.5mg/mL (2,500mcg/mL) working concentration. Swirl gently — do not shake.
Storage reference
Lyophilised: refrigerate at 2–8°C (stable up to approximately 24 months); avoid freeze-thaw cycles. Reconstituted: store at 2–8°C, protect from light, and use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Theoretical VEGF/angiogenesis concern noted in 2025 reviews — precautionary for subjects with pre-existing neoplastic tissue.
Efficacy data is primarily preclinical (rodent); no completed human RCTs as of mid-2025.
Mild nausea has been reported anecdotally at higher doses; tolerability is otherwise considered favourable in animal research.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading